SCHEDULE 13G/A: L1 Capital Global Opportunities Master Fund Significantly Reduces Stake in AEON Biopharma

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, revealing a substantial reduction in its beneficial ownership of AEON Biopharma, Inc.'s Class A Common Stock to 4.11%.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. has filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in AEON Biopharma, Inc.
• The filing indicates that L1 Capital Global Opportunities Master Fund, Ltd. now beneficially owns 465,029 warrants of AEON Biopharma, Inc.'s Class A Common Stock.
• This ownership represents 4.11% of the Class A Common Stock outstanding.
• The previous Schedule 13G, filed on January 13, 2025, covered 8,960,000 shares of Common Stock and underlying Warrants purchased on January 6, 2025.
• The current percentage of class (4.11%) is based on 11,305,367 Class A Common Stock outstanding as of May 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 14, 2025.
• L1 Capital Global Opportunities Master Fund, Ltd. holds sole voting and sole dispositive power over all 465,029 warrants.
• David Feldman and Joel Arber are Directors of L1 Capital Global Opportunities Master Fund, Ltd. and disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant reduction in beneficial ownership by a major institutional investor, which could signal a loss of confidence or a change in investment strategy regarding the issuer.

Positives

• An institutional investor, L1 Capital Global Opportunities Master Fund, Ltd., continues to hold a stake in AEON Biopharma, Inc., indicating some level of continued interest.

Negatives

• L1 Capital Global Opportunities Master Fund, Ltd. has significantly reduced its beneficial ownership in AEON Biopharma, Inc. from 8,960,000 shares/warrants reported in its January 13, 2025 filing to 465,029 warrants as of March 31, 2025.
• The current ownership of 4.11% is below the 5% threshold, which typically reduces the reporting requirements for the investor.

Risks

• The substantial reduction in beneficial ownership by a significant institutional investor could be perceived negatively by the market, potentially impacting investor confidence and the company's stock price.

Future Outlook

This document does not contain forward-looking statements or guidance regarding the company's operations or financial performance.

Management Comments

• David Feldman and Joel Arber, Directors of L1 Capital Global Opportunities Master Fund, Ltd., disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

Industry Context

This filing reflects a change in institutional investor positioning within the biotechnology or biopharmaceutical sector, indicating a shift in a specific fund's investment strategy or outlook regarding AEON Biopharma, Inc. It does not provide broader industry trends.

Stakeholder Impact

• Shareholders: The significant reduction in a major institutional investor's stake could lead to negative market sentiment and potentially impact the share price.

Key Dates

Keywords

AEON Biopharma, L1 Capital Global Opportunities Master Fund, Schedule 13G, beneficial ownership, Class A Common Stock, warrants, institutional investment, ownership change